Skip to main content
. Author manuscript; available in PMC: 2018 Jun 1.
Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2017 Jan 11;26(6):945–952. doi: 10.1158/1055-9965.EPI-16-0948

Table 4.

ORs (95% CIs) of colorectal cancer ranked by quartile of serum carnitine and betaine

OR (95% CI) by quartile of serum biomarker (µmol/L)
Carnitine N 1 (≤29.8) 2 (>29.8 to 33.5) 3 (>33.5 to 38.3) 4 (>38.3) P
trend

Colorectal cancer
No. cases/
No. controls
644/644 157/161 151/161 178/161 158/161
Age and batch adjusted 644/644 1.00 (Ref.) 0.97 (0.70–1.35) 1.15 (0.83–1.59) 1.02 (0.73–1.43) 0.74
Fully adjusteda 642/643 1.00 (Ref.) 0.97 (0.70–1.35) 1.15 (0.83–1.59) 1.03 (0.73–1.44) 0.71

Cancer of the Proximal Colon
No. cases/
No. controls
169/169 38/50 42/46 50/34 39/39
Age and batch adjusted 169/169 1.00 (Ref.) 1.34 (0.70–2.59) 2.22 (1.13–4.36) 1.44 (0.72–2.87) 0.16
Fully adjusteda 169/169 1.00 (Ref.) 1.33 (0.69–2.58) 2.21 (1.12–4.34) 1.42 (0.71–2.84) 0.17

Cancer of the Distal Colon
No. cases/
No. controls
153/153 42/36 25/42 46/41 40/34
Age and batch adjusted 153/153 1.00 (Ref.) 0.49 (0.24–1.00) 0.96 (0.49–1.89) 1.05 (0.50–2.20) 0.60
Fully adjusteda 152/153 1.00 (Ref.) 0.49 (0.24–1.02) 0.97 (0.49–1.90) 1.06 (0.51–2.22) 0.60

Cancer of the Rectum
No. cases/
No. controls
282/282 69/66 73/62 70/77 70/77
Age and batch adjusted 282/282 1.00 (Ref.) 1.12 (0.67–1.85) 0.85 (0.51–1.41) 0.84 (0.51–1.40) 0.37
Fully adjusteda 281/281 1.00 (Ref.) 1.15 (0.69–1.91) 0.84 (0.51–1.41) 0.85 (0.51–1.41) 0.37

Betaine N 1 (≤24.75) 2 (>24.75 to
30.62)
3 (>30.62 to
37.56)
4 (>37.56) P
trend

Colorectal cancer
No. cases/
No. controls
644/644 152/161 169/161 154/161 169/161
Age and batch adjusted 644/644 1.00 (Ref.) 1.12 (0.82–1.54) 1.02 (0.74–1.41) 1.13 (0.82–1.56) 0.58
Fully adjusteda 642/643 1.00 (Ref.) 1.12 (0.82–1.53) 1.02 (0.74–1.40) 1.12 (0.81–1.55) 0.61

Cancer of the Proximal
Colon
No. cases/
No. controls
169/169 40/49 41/31 43/45 45/44
Age and batch adjusted 169/169 1.00 (Ref.) 1.68 (0.87–3.23) 1.20 (0.64–2.25) 1.33 (0.69–2.53) 0.62
Fully adjusteda 169/169 1.00 (Ref.) 1.71 (0.88–3.30) 1.24 (0.66–2.33) 1.34 (0.70–2.57) 0.60

Cancer of the Distal
Colon
No. cases/
No. controls
153/153 38/37 41/40 34/40 40/36
Age and batch adjusted 153/153 1.00 (Ref.) 1.00 (0.52–1.92) 0.81 (0.41–1.58) 1.11 (0.57–2.18) 0.83
Fully adjusteda 152/153 1.00 (Ref.) 1.00 (0.52–1.93) 0.79 (0.40–1.57) 1.17 (0.59–2.31) 0.73

Rectal Cancer
No. cases/
No. controls
282/282 62/60 81/78 68/67 71/71
Age and batch adjusted 282/282 1.00 (Ref.) 1.12 (0.69–1.82) 1.09 (0.66–1.81) 1.08 (0.65–1.80) 0.86
Fully adjusteda 281/281 1.00 (Ref.) 1.10 (0.68–1.78) 1.05 (0.63–1.75) 1.02 (0.61–1.71) 0.98

Logistic regression models adjusted for batch (categorical, 27 batches) and age (continuous). Quartiles of serum carnitine were based on the distribution among controls. Medians for each quartile (based on controls) were used in trend test; medians for carnitine quartiles 1 through 4 were 26.4, 31.9, 35.5 and 41.1, respectively; medians for betaine quartiles 1 through 4 were 24.75, 30.62 and 37.56, respectively.

*

P<0.0001

**

P<0.001

a

Model additionally adjusted for the number of years smoked regularly (continuous), number of cigarettes smoked per day (continuous), education (college graduate, some college or technical school, versus ≤ high school), body mass index (continuous, kg/m2), heavy physical activity in leisure (yes/no), heavy occupational physical activity (yes/no), physical activity frequency (≥3 times per week, versus <3), total energy intake (continuous, kcal/day)